Centaurus Financial, Inc. Tg Therapeutics, Inc. Transaction History

Centaurus Financial, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$15.2 - $35.51 $380,988 - $890,058	-25,065 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$21.78 - $40.45 $1,415 - $2,629	65 Added 0.26%	25,065 $834,000
Q2 2021 Aug 10, 2021	SELL	$32.5 - $48.96 $32,500 - $48,960	-1,000 Reduced 3.85%	25,000 $970,000
Q3 2020 Nov 12, 2020	BUY	$18.49 - $27.24 $110,939 - $163,440	6,000 Added 30.0%	26,000 $696,000
Q2 2020 Aug 13, 2020	BUY	$8.9 - $21.84 $44,500 - $109,200	5,000 Added 33.33%	20,000 $390,000
Q1 2020 Apr 21, 2020	BUY	$7.14 - $15.99 $35,700 - $79,950	5,000 Added 50.0%	15,000 $148,000
Q2 2019 Aug 15, 2019	BUY	$6.27 - $8.65 $62,198 - $85,808	9,920 Added 12400.0%	10,000 $87,000
Q1 2019 Jul 01, 2019	SELL	$4.02 - $8.04 $39,878 - $79,756	-9,920 Reduced 99.2%	80 $10 Million
Q1 2019 May 13, 2019	BUY	$4.02 - $8.04 $40,199 - $80,399	10,000 New	10,000 $80,000

373

85.6M

3.78M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.79B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.